Novo Nordisk announced that it has received approval for the price of Victoza, a once-daily human GLP-1 analogue for the treatment of type 2 diabetes, from Japan’s Central Social Insurance Medical Council (Chuikyo), the advisory committee to the Minister of Health, Labour and Welfare. The price approval allows Novo Nordisk to commercially launch in Japan shortly after Victoza is officially posted on Japan’s National Health Insurance price list on June 11th.
Victoza was approved by the Minister of Health, Labour and Welfare on January 20, 2010 based on a clinical development program specifically tailored to the needs of people with type 2 diabetes in Japan.
